DiscoveRx to Provide GSK with GPCR Screening Tech | GenomeWeb

NEW YORK (GenomeWeb News) – DiscoveRx said today that it will provide GlaxoSmithKline with cell lines and reagents for G-protein coupled receptor screening.

Under the worldwide pact, DiscoveRx, based in Fremont, Calif., will provide GSK with access to its PathHunter beta-arresting parental cell lines, clones, and associated reagents for use in GSK's internal GPCR screening and profiling efforts.

Financial terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.